Evidence map›Paper›PMID 25605250›Full record

ArticleOncotarget2015

Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.

Vidya P Ramamurthy, Senthilmurugan Ramalingam, Lalji Gediya, Andrew K Kwegyir-Afful, Vincent C O Njar

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer.International journal of molecular sciences · 2020
    Review
  9. Article
  10. Article
  11. Review
  12. eIF4E Phosphorylation in Prostate Cancer.Neoplasia (New York, N.Y.) · 2018
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Vidya P RamamurthyDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.
Senthilmurugan RamalingamDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.
Lalji GediyaDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.
Andrew K Kwegyir-AffulDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.
Vincent C O NjarDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.
University of Maryland, Baltimore · US

Funding

Development of VN/14-1 and Related Analogs for Breast Cancer TherapyR01CA129379 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI NJAR, VINCENT COLLINS OFUKA · 2010 to 2014
$2.5M
NCI NIH HHS R01 CA129379NCI NIH HHS R01CA129379
6 · The paper itself

Abstract

Androgen receptor (AR) and MNK activated eIF4E signaling promotes the development and progression of prostate cancer (PCa). In this study, we report that our Novel Retinamides (NRs) target both AR signaling and eIF4E translation in androgen sensitive and castration resistant PCa cells via enhancing AR and MNK degradation through ubiquitin-proteasome pathway. Dual blockade of AR and MNK initiated eIF4E activation by NRs in turn induced cell cycle arrest, apoptosis, and inhibited cell proliferation. NRs also inhibited cell migration and invasion in metastatic cells. Importantly, the inhibitory effects of NRs on AR signaling, eIF4E translation initiation and subsequent oncogenic program were more potent than that observed with clinically relevant retinoids, established MNK inhibitors, and the FDA approved PCa drugs. Our findings provide the first preclinical evidence that simultaneous inhibition of AR and eIF4E activation is a novel and efficacious therapeutic approach for PCa, and that NRs hold significant promise for treatment of advanced prostate cancer.

Indexed as

Androgen AntagonistsAntineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationDose-Response Relationship, DrugEukaryotic Initiation Factor-4EGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMaleNeoplasms, Hormone-DependentProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAndrogen AntagonistsAntineoplastic AgentsAR protein, humanEukaryotic Initiation Factor-4EIntracellular Signaling Peptides and ProteinsMKNK1 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesReceptors, AndrogenretinamideTretinoin

Identifiers

PMID25605250
PMCPMC4413647
OpenAlexW1593311306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.